Ana Luiza Chaves Valadão
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ana Luiza Chaves Valadão has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Antoine Rebendenne
IRIM, Univ Montpellier, CNRS, Montpellier, France
3 shared publications - Caroline Goujon
IRIM, Univ Montpellier, CNRS, Montpellier, France
3 shared publications - Joe McKellar
Institut de Génétique Moléculaire de Montpellier (IGMM), Université de Montpellier, Centre National de la Recherche Scientifique (CNRS) UMR5535 1 , Montpellier
3 shared publications - Olivier Moncorgé
IRIM, CNRS, Montpellier University, France
3 shared publications - Boris Bonaventure
Icahn School of Medicine at Mount Sinai, Department of Microbiology and Global Heath and Emerging Pathogens Institute, New York, NY, 10029, United States of America
2 shared publications - Francisco Garcia de Gracia
IRIM, CNRS, Montpellier University, France
2 shared publications
Latest Publications
- Open Access
SARS-CoV-2 predation of Golgi-bound PI4P primes the massive activation of the DNA Damage Response kinase ATM in the cytoplasm
Like all viruses, SARS-CoV-2, the causative agent of COVID-19, relies on host cell resources to replicate. Our study reveals that, among these resources, SARS-CoV-2 hijacks the oxysterol-binding protein 1 (OSBP1) transporter to exploit the Golgi-bound phosphatidylinositol-4-phosphate (PI4P) pool. This leads to a depletion of Golgi-resident PI4P, triggering the activation of the ATM DNA Damage Response (DDR) kinase in the cytoplasm. As such, ATM, typically anchored to PI4P at the Golgi in an inactive state, undergoes auto-phosphorylation and cytoplasmic release upon SARS-CoV-2-induced PI4P depletion. Conversely, pharmacological inhibition of ATM auto-phosphorylation, which stabilizes its interaction with PI4P, significantly impairs SARS-CoV-2 replication. The requirement for PI4P and impact of ATM inhibition might be conserved across coronaviruses, as similar effects were observed with HCoV-229E. Finally, SARS-CoV-2-induced, cytoplasmic ATM pre-activation primes cells for an accelerated response to DNA damage, which might contribute to the severe outcomes of COVID-19 observed in cancer patients undergoing chemo- or radiotherapy. Therefore, this study uncovers a DNA damage-independent mode of ATM activation and highlights the potential of ATM inhibitors as therapeutic agents against COVID-19.
Open AccessSARS-CoV-2 predation of Golgi-bound PI4P primes the massive activation of the DNA Damage Response kinase ATM in the cytoplasm
Like all viruses, SARS-CoV-2, the causative agent of COVID-19, relies on host cell resources to replicate. Our study reveals that, among these resources, SARS-CoV-2 hijacks the oxysterol-binding protein 1 (OSBP1) transporter to exploit the Golgi-bound phosphatidylinositol-4-phosphate (PI4P) pool. This leads to a depletion of Golgi-resident PI4P, triggering the activation of the ATM DNA Damage Response (DDR) kinase in the cytoplasm. As such, ATM, typically anchored to PI4P at the Golgi in an inactive state, undergoes auto-phosphorylation and cytoplasmic release upon SARS-CoV-2-induced PI4P depletion. Conversely, pharmacological inhibition of ATM auto-phosphorylation, which stabilizes its interaction with PI4P, significantly impairs SARS-CoV-2 replication. The requirement for PI4P and impact of ATM inhibition might be conserved across coronaviruses, as similar effects were observed with HCoV-229E. Finally, SARS-CoV-2-induced, cytoplasmic ATM pre-activation primes cells for an accelerated response to DNA damage, which might contribute to the severe outcomes of COVID-19 observed in cancer patients undergoing chemo- or radiotherapy. Therefore, this study uncovers a DNA damage-independent mode of ATM activation and highlights the potential of ATM inhibitors as therapeutic agents against COVID-19.
- Open Access
Human MX1 orchestrates the cytoplasmic sequestration of neo-synthesized influenza A virus vRNPs
Interferon-inducible Myxovirus resistance 1 (MX1) proteins are well-known to restrict influenza A virus (IAV) at early stages during viral replication, impairing the viral transcription/replication process. Herein, we show that this early restriction was only partial against human IAVs, whereas a strong inhibition of viral production was observed. Indeed, relatively high levels of IAV mRNAs and proteins were observed in the presence of human (Hs) and mouse (Mm) MX1 proteins but additional inhibition processes occurred at later stages of IAV life cycle. Hence, MmMx1 induced an abnormal nuclear accumulation of the viral nucleoprotein (NP) at late time points post-infection. This block was also observed, albeit to a much lower extent, with HsMX1. In most HsMX1-expressing cells, vRNPs could be exported from the nucleus to the cytoplasm however a potent defect in subsequent vRNP cytoplasmic trafficking was observed. Indeed, vRNPs were found sequestrated together with cellular co-factors YBX1 and Rab11a in large clusters in the vicinity of the microtubule organization center (MTOC). Live imaging experiments revealed that the transient association of HsMX1 with Rab11a-associated vRNPs favoured their dynein-dependant retrograde transport along microtubules towards the MTOC. Importantly, dynein inhibition prevented the vRNP sequestration and significantly rescued infectious viral production in the presence of HsMX1, showing a significant contribution of these abnormal vRNP clusters in HsMX1 antiviral activity. In conclusion, this study provides the first evidence of IAV vRNPs being re-routed and accumulated away from the plasma membrane, through the coordinated action of HsMX1 restriction factor, dynein and the microtubule network.
Open AccessHuman MX1 orchestrates the cytoplasmic sequestration of neo-synthesized influenza A virus vRNPs
Interferon-inducible Myxovirus resistance 1 (MX1) proteins are well-known to restrict influenza A virus (IAV) at early stages during viral replication, impairing the viral transcription/replication process. Herein, we show that this early restriction was only partial against human IAVs, whereas a strong inhibition of viral production was observed. Indeed, relatively high levels of IAV mRNAs and proteins were observed in the presence of human (Hs) and mouse (Mm) MX1 proteins but additional inhibition processes occurred at later stages of IAV life cycle. Hence, MmMx1 induced an abnormal nuclear accumulation of the viral nucleoprotein (NP) at late time points post-infection. This block was also observed, albeit to a much lower extent, with HsMX1. In most HsMX1-expressing cells, vRNPs could be exported from the nucleus to the cytoplasm however a potent defect in subsequent vRNP cytoplasmic trafficking was observed. Indeed, vRNPs were found sequestrated together with cellular co-factors YBX1 and Rab11a in large clusters in the vicinity of the microtubule organization center (MTOC). Live imaging experiments revealed that the transient association of HsMX1 with Rab11a-associated vRNPs favoured their dynein-dependant retrograde transport along microtubules towards the MTOC. Importantly, dynein inhibition prevented the vRNP sequestration and significantly rescued infectious viral production in the presence of HsMX1, showing a significant contribution of these abnormal vRNP clusters in HsMX1 antiviral activity. In conclusion, this study provides the first evidence of IAV vRNPs being re-routed and accumulated away from the plasma membrane, through the coordinated action of HsMX1 restriction factor, dynein and the microtubule network.
- Open Access
Bidirectional genome-wide CRISPR screens reveal host factors regulating SARS-CoV-2, MERS-CoV and seasonal coronaviruses
Several genome-wide CRISPR knockout screens have been conducted to identify host factors regulating SARS-CoV-2 replication, but the models used have often relied on overexpression of ACE2 receptor. Additionally, such screens have yet to identify the protease TMPRSS2, known to be important for viral entry at the plasma membrane. Here, we conducted a meta-analysis of these screens and showed a high level of cell-type specificity of the identified hits, arguing for the necessity of additional models to uncover the full landscape of SARS-CoV-2 host factors. We performed genome-wide knockout and activation CRISPR screens in Calu-3 lung epithelial cells, as well as knockout screens in Caco-2 intestinal cells. In addition to identifying ACE2 and TMPRSS2 as top hits, our study reveals a series of so far unidentified and critical host-dependency factors, including the Adaptins AP1G1 and AP1B1 and the flippase ATP8B1. Moreover, new anti-SARS-CoV-2 proteins with potent activity, including several membrane-associated Mucins, IL6R, and CD44 were identified. We further observed that these genes mostly acted at the critical step of viral entry, with the notable exception of ATP8B1, the knockout of which prevented late stages of viral replication. Exploring the pro- and anti-viral breadth of these genes using highly pathogenic MERS-CoV, seasonal HCoV-NL63 and -229E and influenza A orthomyxovirus, we reveal that some genes such as AP1G1 and ATP8B1 are general coronavirus cofactors. In contrast, Mucins recapitulated their known role as a general antiviral defense mechanism. These results demonstrate the value of considering multiple cell models and perturbational modalities for understanding SARS-CoV-2 replication and provide a list of potential new targets for therapeutic interventions.
Open AccessBidirectional genome-wide CRISPR screens reveal host factors regulating SARS-CoV-2, MERS-CoV and seasonal coronaviruses
Several genome-wide CRISPR knockout screens have been conducted to identify host factors regulating SARS-CoV-2 replication, but the models used have often relied on overexpression of ACE2 receptor. Additionally, such screens have yet to identify the protease TMPRSS2, known to be important for viral entry at the plasma membrane. Here, we conducted a meta-analysis of these screens and showed a high level of cell-type specificity of the identified hits, arguing for the necessity of additional models to uncover the full landscape of SARS-CoV-2 host factors. We performed genome-wide knockout and activation CRISPR screens in Calu-3 lung epithelial cells, as well as knockout screens in Caco-2 intestinal cells. In addition to identifying ACE2 and TMPRSS2 as top hits, our study reveals a series of so far unidentified and critical host-dependency factors, including the Adaptins AP1G1 and AP1B1 and the flippase ATP8B1. Moreover, new anti-SARS-CoV-2 proteins with potent activity, including several membrane-associated Mucins, IL6R, and CD44 were identified. We further observed that these genes mostly acted at the critical step of viral entry, with the notable exception of ATP8B1, the knockout of which prevented late stages of viral replication. Exploring the pro- and anti-viral breadth of these genes using highly pathogenic MERS-CoV, seasonal HCoV-NL63 and -229E and influenza A orthomyxovirus, we reveal that some genes such as AP1G1 and ATP8B1 are general coronavirus cofactors. In contrast, Mucins recapitulated their known role as a general antiviral defense mechanism. These results demonstrate the value of considering multiple cell models and perturbational modalities for understanding SARS-CoV-2 replication and provide a list of potential new targets for therapeutic interventions.